About amarillo biosciences inc. - AIMD
Ainos, Inc. operates as a dual-platform biotech company, which engages in the development of artificial intelligence-enabled olfactory sensing technologies and immune therapeutics. The firm primarily focuses on the commercialization of AI Nose, an AI-based electronic olfaction system. It continues to develop VELDONA, a low-dose oral interferon platform. The company was founded on June 26, 1984 and is headquartered in Houston, TX.
AIMD At a Glance
Ainos, Inc.
3050 Post Oak Boulevard
Houston, Texas 92108
| Phone | 1-281-898-6586 | Revenue | 124.16K | |
| Industry | Electronic Equipment/Instruments | Net Income | -14,771,012.00 | |
| Sector | Electronic Technology | 2025 Sales Growth | 498.953% | |
| Fiscal Year-end | 12 / 2026 | Employees | 41 | |
| View SEC Filings |
AIMD Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 56.414 |
| Price to Book Ratio | 1.276 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.909 |
| Enterprise Value to Sales | 141.65 |
| Total Debt to Enterprise Value | 0.625 |
AIMD Efficiency
| Revenue/Employee | 3,028.22 |
| Income Per Employee | -360,268.585 |
| Receivables Turnover | 5,643.50 |
| Total Asset Turnover | 0.005 |
AIMD Liquidity
| Current Ratio | 1.056 |
| Quick Ratio | 0.782 |
| Cash Ratio | 0.387 |
AIMD Profitability
| Gross Margin | -3,767.197 |
| Operating Margin | -11,268.322 |
| Pretax Margin | -11,896.399 |
| Net Margin | -11,897.043 |
| Return on Assets | -59.451 |
| Return on Equity | -128.005 |
| Return on Total Capital | -79.574 |
| Return on Invested Capital | -68.577 |
AIMD Capital Structure
| Total Debt to Total Equity | 145.453 |
| Total Debt to Total Capital | 59.259 |
| Total Debt to Total Assets | 52.704 |
| Long-Term Debt to Equity | 145.453 |
| Long-Term Debt to Total Capital | 59.259 |